The Armour Group was founded with the simple and ground-breaking vision of using the power of the endocannabinoid system to improve the quality of lives for patients. The knowledge existed, and with archaic legislation finally thawing, The Armour Group was able to start paving the way for cannabis pharmaceuticals in Europe. It is a privilege for us to be able to provide so much relief for so many, and we look forward to the future.
Built the company that would aim to start paving the way for cannabis in Europe for the benefits of patients of all kinds.
The company’s focus was evident from day one, the vision was refined and leveraged.
Through relationships, both old and new, The Armour Group was able to procure supply chain components and contracts in times of supply chain chaos. We believe this is a testament to The Armour Groups resilience, resourcefulness, and receptive.
Understanding that the lessons of the pandemic and challenges that confront contemporary distribution chains, The Armour Group completed a distribution chain that was designed for resilience – consistency in distribution for patients was a critical point of The Armour Groups infrastructure.
Building upon The Armour Groups relationships in Germany, we achieved our wholesale license to be able to distribute and operate in the largest economy and market in Europe.
The board was appointed with the understanding that knowledge is critical. This provides the company with very strong leverage to understand key challenges that face our patients and our partners.
Launch our series of extracts into the UK and German markets.
Launch our series of extracts into the UK markets.
Paving the way for medicinal cannabis
© 2022 The Armour Group. The Armour G Limited. is registered in England and Wales. Kemp House, 160 City Road, London, England, EC1V 2NX. Company number 12005014.
